Immunotherapy with Dendritic Cells Directed Against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2000 Mar 8

PMID 10704461

Citations 45

Authors

B Ludewig

A F Ochsenbein

B Odermatt

D Paulin

H Hengartner

R M Zinkernagel

Affiliations

Soon will be listed here.

Abstract

Vaccination with dendritic cells (DCs) presenting tumor antigens induces primary immune response or amplifies existing cytotoxic antitumor T cell responses. This study documents that antitumor treatment with DCs may cause severe autoimmune disease when the tumor antigens are not tumor-specific but are also expressed in peripheral nonlymphoid organs. Growing tumors with such shared tumor antigens that were, at least initially, strictly located outside of secondary lymphoid organs were successfully controlled by specific DC vaccination. However, antitumor treatment was accompanied by fatal autoimmune disease, i.e., autoimmune diabetes in transgenic mice expressing the tumor antigen also in pancreatic beta islet cells or by severe arteritis, myocarditis, and eventually dilated cardiomyopathy when arterial smooth muscle cells and cardiomyocytes expressed the transgenic tumor antigen. These results reveal the delicate balance between tumor immunity and autoimmunity and therefore point out important limitations for the use of not strictly tumor-specific antigens in antitumor vaccination with DCs.

Citing Articles

Dendritic Cells: A Bridge between Tolerance Induction and Cancer Development in Transplantation Setting.

Troise D, Infante B, Mercuri S, Catalano V, Ranieri E, Stallone G Biomedicines. 2024; 12(6).

PMID: 38927447 PMC: 11200833. DOI: 10.3390/biomedicines12061240.

Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots.

Weiden J, Schluck M, Ioannidis M, van Dinther E, Rezaeeyazdi M, Omar F ACS Biomater Sci Eng. 2021; 7(12):5622-5632.

PMID: 34734689 PMC: 8672349. DOI: 10.1021/acsbiomaterials.0c01648.

Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack.

Bonilla W, Kirchhammer N, Marx A, Kallert S, Krzyzaniak M, Lu M Cell Rep Med. 2021; 2(3):100209.

PMID: 33763654 PMC: 7974551. DOI: 10.1016/j.xcrm.2021.100209.

Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens.

de Waard A, Verkerk T, Hoefakker K, van der Steen D, Jongsma M, Melamed Kadosh D iScience. 2021; 24(2):102051.

PMID: 33554062 PMC: 7847959. DOI: 10.1016/j.isci.2021.102051.

Tumor-Derived Apoptotic Vesicles: With Death They Do Part.

Muhsin-Sharafaldine M, McLellan A Front Immunol. 2018; 9:957.

PMID: 29780392 PMC: 5952256. DOI: 10.3389/fimmu.2018.00957.

References

Ohashi P, Oehen S, BUERKI K, Pircher H, Ohashi C, Odermatt B . Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991; 65(2):305-17. DOI: 10.1016/0092-8674(91)90164-t. View

Prehn R, MAIN J . Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957; 18(6):769-78. View

Darnell R, DeAngelis L . Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet. 1993; 341(8836):21-2. DOI: 10.1016/0140-6736(93)92485-c. View

Hu J, Kindsvogel W, Busby S, BAILEY M, Shi Y, Greenberg P . An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med. 1993; 177(6):1681-90. PMC: 2191055. DOI: 10.1084/jem.177.6.1681. View

Houghton A . Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994; 180(1):1-4. PMC: 2191545. DOI: 10.1084/jem.180.1.1. View

Cobbold S, Jayasuriya A, Nash A, Prospero T, Waldmann H . Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984; 312(5994):548-51. DOI: 10.1038/312548a0. View

Oehen S, Ohashi P, Burki K, Hengartner H, Zinkernagel R, Aichele P . Escape of thymocytes and mature T cells from clonal deletion due to limiting tolerogen expression levels. Cell Immunol. 1994; 158(2):342-52. DOI: 10.1006/cimm.1994.1281. View

Kundig T, Bachmann M, DiPaolo C, Simard J, Battegay M, Lother H . Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 1995; 268(5215):1343-7. DOI: 10.1126/science.7761853. View

Mayordomo J, Zorina T, Storkus W, Zitvogel L, Celluzzi C, Falo L . Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995; 1(12):1297-302. DOI: 10.1038/nm1295-1297. View

10.

Zitvogel L, Mayordomo J, Tjandrawan T, DeLeo A, Clarke M, Lotze M . Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996; 183(1):87-97. PMC: 2192415. DOI: 10.1084/jem.183.1.87. View

11.

Oukka M, Cohen-Tannoudji M, Tanaka Y, Babinet C, Kosmatopoulos K . Medullary thymic epithelial cells induce tolerance to intracellular proteins. J Immunol. 1996; 156(3):968-75. View

12.

Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, Small J . The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development. 1996; 122(8):2415-25. DOI: 10.1242/dev.122.8.2415. View

13.

Rosenberg S, White D . Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996; 19(1):81-4. View

14.

Ropke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L . Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A. 1996; 93(25):14704-7. PMC: 26199. DOI: 10.1073/pnas.93.25.14704. View

15.

Wang R, Appella E, Kawakami Y, Kang X, Rosenberg S . Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996; 184(6):2207-16. PMC: 2211562. DOI: 10.1084/jem.184.6.2207. View

16.

Bloom M, Robbins P, Li Y, Rosenberg S, Yang J . Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997; 185(3):453-9. PMC: 2196033. DOI: 10.1084/jem.185.3.453. View

17.

Kurts C, Heath W, Carbone F, Allison J, Miller J, Kosaka H . Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med. 1996; 184(3):923-30. PMC: 2192761. DOI: 10.1084/jem.184.3.923. View

18.

Gong J, Chen D, Kashiwaba M, Kufe D . Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997; 3(5):558-61. DOI: 10.1038/nm0597-558. View

19.

Zinkernagel R, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H . Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997; 156:199-209. DOI: 10.1111/j.1600-065x.1997.tb00969.x. View

20.

Speiser D, Miranda R, Zakarian A, Bachmann M, Odermatt B, Hanahan D . Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 1997; 186(5):645-53. PMC: 2199023. DOI: 10.1084/jem.186.5.645. View